Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs

SIMPLE SUMMARY: Drug resistance is the “Achilles’ heel” in current oncology. In this sense, the clinical management of HER2 breast carcinomas (tumors with overexpression/amplification of the ErbB2/HER2 oncogene) is still a challenge. Although a variety of anti-HER2 therapies (anti-HER2 antibodies, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gámez-Chiachio, Manuel, Sarrió, David, Moreno-Bueno, Gema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496705/
https://www.ncbi.nlm.nih.gov/pubmed/36139701
http://dx.doi.org/10.3390/cancers14184543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496705/
https://www.ncbi.nlm.nih.gov/pubmed/36139701
http://dx.doi.org/10.3390/cancers14184543

Ejemplares similares